Risk factors
CytomX Therapeutics (CTMX) risk factors
Item 1A of every CytomX Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors83 risks11 new9 dropped21 reworded
CytomX faces significant funding runway pressures, relying on $137.1 million to fund operations into the second quarter of 2027.
Filed Mar 16, 2026 - FY2024 10-K risk factors81 risks
Clinical development relies heavily on unproven PROBODY platforms and single-source foreign contract manufacturers. Collaborations with partners like Amgen, AbbVie, Regeneron, and Moderna drive key pipeline programs. Operations are concentrated in South San Francisco with key patent dependencies on Amgen, ImmunoGen, and UCSB.
Filed Mar 06, 2025